^
Association details:
| Biomarker: | MYC overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Kymriah (tisagenlecleucel-T) (CD19-targeted CAR-T immunotherapy) |
| Direction: | Resistant |
Evidence:
Source:
Title:
212 - Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Juliet Trial
Published date:
01/13/2021
Excerpt:
The relationship between Myc overexpression (Myc+ >40%), TME characteristics (CD3+ T-cell infiltration, myeloid-derived suppressor cells, and LAG3 expression) with efficacy outcomes...At median follow-up 40.3mo (Feb 20, 2020), 115 pts received tisa-cel....Pts with Myc− status and normal pre-infusion LDH levels (n=16) had longer PFS vs normal LDH and Myc+; pts with LDH 1- 2 / >2-fold above the upper limit of normal had poor PFS.
